Effectiveness and safety of encorafenib-cetuximab in BRAFV600E metastatic colorectal cancer: Confidence study.

被引：0
|
作者：
Fernandez Montes, Ana
Ros, Javier
Grana, Begona
Garcia-Alfonso, Pilar
Brozos, Elena
Melian, Marcos
Jimenez-Gordo, Ana M.
Martinez de Castro, Eva
Busquier, Isabel
Gallego, Javier
Gravalos, Cristina
Covela, Marta
Ruiz-Casado, Ana
Gonzalez Flores, Encarnacion
Safont, Mariajose
Maria Cano, Juana
Alonso Lopez, Carmen
Gomez-Reina, Maria Jose
Donnay, Olga
Aranda, Enrique
机构：
[1] Complexo Hosp Univ Ourense CHUO, Dept Med Oncol, Orense, Spain
[2] Vall dHebron Univ Hosp CHUO, Dept Med Oncol, Barcelona, Spain
[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[4] A Coruna Univ Hosp, Inst Invest Biomed INIBIC, La Coruna, Spain
[5] Hosp Univ Gregorio Maranon, Dept Med Oncol, Madrid, Spain
[6] CHUS, Santiago De Compostela, Spain
[7] Inst Valenciano Oncol, Valencia, Spain
[8] Hosp Univ Infanta Sofia, Dept Med Oncol, San Sebastian Los Reyes, Spain
[9] Univ Hosp Marques de Valdecilla, Dept Med Oncol, IDIVAL, Santander, Spain
[10] Hosp Prov Castellon, Valencia, Spain
[11] Hosp Gen Univ Elche, Alicante, Spain
[12] Hosp Univ 12 Octubre, Madrid, Spain
[13] Hosp Univ Lucas Augusti HULA, Lugo, Spain
[14] Hosp Univ Puerta de Hierro, Dept Med Oncol, Madrid, Spain
[15] Hosp Virgen de las Nieves, Granada, Spain
[16] Hosp Gen Valencia, Valencia, Spain
[17] Hosp Gen Univ Ciudad Real, Ciudad Real, Spain
[18] Complejo Hosp Univ Albacete, Albacete, Spain
[19] Hosp Univ Nuestra Senora de Valme, Seville, Spain
[20] Hosp Univ Princesa, Madrid, Spain
[21] Hosp Univ Reina Sofia, Cordoba, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
126
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [31] SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer
    Morris, Van K., II
    Guthrie, Katherine A.
    Kopetz, Scott
    Breakstone, Rimini
    Karasic, Thomas Benjamin
    Hu, Zishuo Ian
    Colby, Sarah
    Fakih, Marwan
    Gholami, Sepideh
    Gold, Philip Jordan
    Chiorean, E. Gabriela
    Philip, Philip A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Nursing care and management of adverse events for patients with BRAFV600E-mutant metastatic colorectal cancer receiving encorafenib in combination with cetuximab: a review
    Fowler, Matthew
    Tobback, Helene
    Karuri, Alice
    Fernandez-Ortega, Paz
    SUPPORTIVE CARE IN CANCER, 2023, 31 (04)
  • [33] BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib plus MEK inhibitor binimetinib plus anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer
    Van Cutsem, E.
    Cuyle, P.
    Huijberts, S.
    Schellens, J.
    Elez, E.
    Yaeger, R.
    Fakih, M.
    Montagut, C.
    Peeters, M.
    Desai, J.
    Yoshino, T.
    Ciardiello, F.
    Wasan, H.
    Maharry, K.
    Christy-Bittel, J.
    Gollerkeri, A.
    Kopetz, S.
    Grothey, A.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [34] Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study
    Taieb, Julien
    Lonardi, Sara
    Desai, Jayesh
    Folprecht, Gunnar
    Gallois, Claire
    Marques, Eduardo Polo
    Khan, Sadya
    Castagne, Claire
    Wasan, Harpreet
    CLINICAL COLORECTAL CANCER, 2023, 22 (01) : 59 - 66
  • [35] Nursing care and management of adverse events for patients with BRAFV600E-mutant metastatic colorectal cancer receiving encorafenib in combination with cetuximab: a review
    Matthew Fowler
    Helene Tobback
    Alice Karuri
    Paz Fernández-Ortega
    Supportive Care in Cancer, 2023, 31
  • [36] Chemotherapy-free Treatment of Patients with BRAFV600E mutated metastatic Colorectal Cancer
    Fabre, Pierre
    VISCERAL MEDICINE, 2020, 36 (03) : 251 - 251
  • [37] Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
    Ros, Javierd
    Saoudi, Nadia
    Baraibar, Iosune
    Salva, Francesc
    Tabernero, Josep
    Elez, Elena
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [38] Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107.
    Morris, Van K.
    Guthrie, Katherine A.
    Kopetz, Scott
    Breakstone, Rimini
    Karasic, Thomas Benjamin
    Hu, Zishuo Ian
    Bellasea, Shay
    Fakih, Marwan
    Gholami, Sepideh
    Gold, Philip Jordan
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS265 - TPS265
  • [39] Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107
    Morris, V.
    Guthrie, K.
    Kopetz, S.
    Breakstone, R.
    Karasic, T.
    Hu, Z.
    Colby, S.
    Fakih, M.
    Gholami, S.
    Gold, P.
    Chiorean, E.
    Philip, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S96 - S96
  • [40] Real-world outcomes in BRAFV600E metastatic colorectal cancer - the Glasgow experience
    Gan, H.
    White, M.
    McGaffin, G.
    Lannagan, T.
    Campbell, A.
    Graham, J.
    Sansom, O.
    Wilson, R.
    ANNALS OF ONCOLOGY, 2022, 33 : S259 - S260
12345